文献速递骨软组织肉瘤与黑色素瘤

免疫检查点抑制剂治疗晚期黑色素瘤合并慢性淋巴细胞白血病患者的疗效

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
PubMed 文献 · Ann Oncol · 2023-07-04

这项国际多中心回顾性研究分析了58例晚期黑色素瘤合并慢性淋巴细胞白血病(CLL)患者接受免疫检查点抑制剂(ICI)的疗效。澳大利亚CLL/AM队列与148例单纯晚期黑色素瘤对照队列的客观缓解率(53% vs 48%,P=0.81)及生存结局相当。既往接受过CLL化学免疫治疗的患者ORR、PFS和OS显著更差。

要点

  • 合并CLL的晚期黑色素瘤患者接受ICI的ORR与单纯黑色素瘤患者相当(53% vs 48%,P=0.81)。
  • 既往因CLL接受化学免疫治疗的患者ORR、PFS和OS显著更差。
  • ICI治疗未明显改变CLL疾病病程。

核心结论

  • 合并CLL的黑色素瘤患者对ICI常见持久临床缓解,但既往接受CLL化学免疫治疗者结局显著更差。
  • ICI治疗未明显改变CLL疾病病程。

研究设计与样本

  • 国际多中心回顾性研究,回顾临床数据库识别接受ICI治疗的CLL合并晚期黑色素瘤患者(美国MD Anderson癌症中心N=24,美国Mayo Clinic N=15,澳大利亚N=19)。
  • 1997年至2020年间共58例CLL合并晚期黑色素瘤患者接受ICI治疗。
  • 将澳大利亚CLL/AM队列与148例澳大利亚单纯晚期黑色素瘤对照队列进行比较。

主要发现

  • 澳大利亚CLL/AM队列与单纯黑色素瘤对照队列的ORR相当(53% vs 48%,P=0.81)。
  • 两队列自ICI启动后的PFS和OS也相当。
  • CLL/AM患者中多数(64%)在ICI治疗时未针对CLL进行治疗。
  • 有CLL化学免疫治疗史的患者(19%)ORR、PFS和OS显著降低。

关键数值与推荐

  • 客观缓解率(ORR)按RECIST v1.1评估。
  • 澳大利亚CLL/AM队列ORR为53%,单纯黑色素瘤对照队列为48%(P=0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been restricted to clinical trials, thereby excluding patients with co-existing malignancies. Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia and is associated with increased risk of melanoma. CLL alters systemic immunity and can induce T-cell exhaustion, which may limit the efficacy of ICIs in patients with CLL. We, therefore, sought to examine the efficacy of ICI in patients with these co-occurring diagnoses. PATIENTS AND METHODS: In this international multicenter study, a retrospective review of clinical databases identified patients with concomitant diagnoses of CLL and AM treated with ICI (US-MD Anderson Cancer Center, N = 24; US-Mayo Clinic, N = 15; AUS, N = 19). Objective response rates (ORRs), assessed by RECIST v1.1, and survival outcomes [overall survival (OS) and progression-free survival (PFS)] among patients with CLL and AM were assessed. Clinical factors associated with improved ORR and survival were explored. Additionally, ORR and survival outcomes were compared between the Australian CLL/AM cohort and a control cohort of 148 Australian patients with AM alone. RESULTS: Between 1997 and 2020, 58 patients with concomitant CLL and AM were treated with ICI. ORRs were comparable between AUS-CLL/AM and AM control cohorts (53% versus 48%, P = 0.81). PFS and OS from ICI initiation were also comparable between cohorts. Among CLL/AM patients, a majority were untreated for their CLL (64%) at the time of ICI. Patients with prior history of chemoimmunotherapy treatment for CLL (19%) had significantly reduced ORRs, PFS, and OS. CONCLUSIONS: Our case series of patients with concomitant CLL and melanoma demonstrate frequent, durable clinical responses to ICI. However, those with prior chemoimmunotherapy treatment for CLL had significantly worse outcomes. We found that CLL disease course is largely unchanged by treatment with ICI.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cass SH, Tobin JWD, Seo YD, et al. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023. PMID: 37414216. doi:10.1016/j.annonc.2023.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。